HispanicBusiness

DAYTONA BEACH, FL -- (Marketwire) -- 08/27/12 -- Quture International, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) and its operations subsidiary Quture, Inc. ("Quture") announce that its QualOptima product is now under contract with the University of Miami Miller School of Medicine and Jackson Memorial Hospital for a clinical trial for performance and outcomes measurement. After completing the demonstration project with InterSystems at the University, the return on investment (ROI) evaluations announced on August 8, 2012, now further include analytics focused on patient-centered, personalized medicine use of the product for hospitals to brand themselves with the same data for their patients.

As announced in June's Shareholder Letter, this additional use of clinical data from QualOptima creates sales incentives to hospitals from data generated by the product in the $700 billion hospital marketing for "branding." QualOptima will be even more on target with the urgent needs of senior management for healthcare analytics.

Quture is in the final stages of ROI evaluations from three hospital reference sites. Use of QualOptima product data for personalized medicine creates yet another financial incentive and investment opportunity for hospitals to license the product. The internal ROI evaluation parallels the Company moving to revenue-based operations as the search for its Chief Business Development Officer is nearing completion. Even at its median price point, the market opportunity for QualOptima is in excess of 1.75 billion dollars annually from hospital sales alone in the United States, and exponentially higher with either revenue model other than traditional licensing or sales to other health care market sectors. Patient-centered, personalized medicine applications create major new market sector opportunities.

In publications by Heather Woodward-Hagg at Purdue University, College of Technology, she has stated their experience with their widely accepted return on investment (ROI) methodology to calculate the business case to promote efficient, patient-centric care within a healthcare organization. In answering the question -- what is preventing the development of the business case for quality in healthcare -- she states: "In our experience, the lack of appropriate performance indicators often makes it difficult to determine performance gaps, effectively drive performance improvements and accurately measure the impact of improvement initiatives."

"Quture is intensely focused on proving and projecting the business case for QualOptima through rigorous ROI methodologies and financial projection models," said Landon Feazell, CEO of Quture International. "We are committed to the use of QualOptima to provide performance measures and analytics tools as already demonstrated in three hospitals. Health care ROI studies and formulas, and now our own ROI calculations prove the clinical logic and business case for QualOptima. Since the product captures and integrates patient-centric risk factors and outcomes measures in addition to performance measures, there is yet another huge intrinsic value for personalized medicine applications of QualOptima data. We are encouraged by the ROI evaluations to date and looking forward to this new financial revenue insight."